EyeWorld Asia-Pacific June 2017 Issue

61 June 2017 EWAP GLAUCOMA Optimal bleb formation after mitomycin-C-augmented trabeculectomy Source (all): Anselm Jünemann, MD Blebitis with large avascular area after mitomycin-C-augmented trabeculectomy Trabeculectomy: Still relevant in the wake of MIGS by Stefanie Petrou Binder, MD EyeWorld Contributing Writer While recognizing its advantages, a German specialist explains why MIGS devices cannot entirely replace trabeculectomy C hange is not always easy to embrace, particularly when your methods are tried and true, reliable and effective. However, the most stubborn nonbelievers cannot deny the stunning IOP relief achieved by microinvasive glaucoma surgery (MIGS). Anselm Jünemann, MD , professor of ophthalmology, Rostock University Eye Clinic, Rostock, Germany, discussed his 180-degree turnaround regarding the role of MIGS devices in modern glaucoma surgery, and why, despite the evidence, he cannot turn his back on trabeculectomy. “We have an abundance of new operative techniques in glaucoma surgery. The question is whether new techniques replace old ones or whether it is prudent to keep the old ones alongside the new, using them as we see fit, according to the level of success or failure we achieve with selected techniques,” Dr. Jünemann said during a presentation he gave on the topic at the 114th Congress of the German Ophthalmological Society, which was held from 29 September to 2 October 2016. The case for MIGS According to Dr. Jünemann, the facts speak loudest. In a prospective open-label randomized study that used the iStent (Glaukos, San Uriant bleb covering the cornea Small avascular bleb after mitomycin-C-augmented trabeculectomy continued on page 62